Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.

Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rötig A, Mayaux MJ, Delfraissy JF.

Lancet. 1999 Sep 25;354(9184):1084-9.

PMID:
10509500
2.
3.

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.

Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage GR 3rd.

AIDS. 2007 May 11;21(8):929-38.

PMID:
17457086
4.

Cerebral MR imaging in uninfected children born to HIV-seropositive mothers and perinatally exposed to zidovudine.

Tardieu M, Brunelle F, Raybaud C, Ball W, Barret B, Pautard B, Lachassine E, Mayaux MJ, Blanche S.

AJNR Am J Neuroradiol. 2005 Apr;26(4):695-701.

5.

Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues.

Thorne C, Newell ML.

Med Wieku Rozwoj. 2003 Oct-Dec;7(4 Pt 1):425-36. Review.

PMID:
15010553
6.

Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.

Aldrovandi GM, Chu C, Shearer WT, Li D, Walter J, Thompson B, McIntosh K, Foca M, Meyer WA 3rd, Ha BF, Rich KC, Moye J Jr.

Pediatrics. 2009 Dec;124(6):e1189-97. doi: 10.1542/peds.2008-2771. Epub 2009 Nov 23.

7.

In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.

Sibiude J, Le Chenadec J, Bonnet D, Tubiana R, Faye A, Dollfus C, Mandelbrot L, Delmas S, Lelong N, Khoshnood B, Warszawski J, Blanche S; French National Agency for Research on AIDS and Viral Hepatitis French Perinatal Cohort/Protease Inhibitor Monotherapy Evaluation Trial..

Clin Infect Dis. 2015 Jul 15;61(2):270-80. doi: 10.1093/cid/civ260. Epub 2015 Apr 1.

PMID:
25838291
8.

Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir.

Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, Nesel CJ, O'Neill JP, Abrams EJ, Poirier MC.

AIDS. 2004 Apr 30;18(7):1013-21.

PMID:
15096804
9.

Zidovudine administration during pregnancy and mitochondrial disease in the offspring.

Tovo PA, Chiapello N, Gabiano C, Zeviani M, Spada M.

Antivir Ther. 2005;10(6):697-9.

PMID:
16218167
10.

Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission.

Briand N, Le Coeur S, Traisathit P, Karnchanamayul V, Hansudewechakul R, Ngampiyasakul C, Bhakeecheep S, Ithisukanan J, Hongsiriwon S, McIntosh K, Lallemant M.

Pediatr Infect Dis J. 2006 Apr;25(4):325-32.

PMID:
16567984
11.

Mitochondrial dysfunction following perinatal exposure to nucleoside analogues.

Blanche S, Tardieu M, Benhammou V, Warszawski J, Rustin P.

AIDS. 2006 Aug 22;20(13):1685-90. No abstract available.

PMID:
16931932
12.

Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.

Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, Dollfus C, Mayaux MJ, Blanche S; French Perinatal Cohort Study Group..

AIDS. 2003 Aug 15;17(12):1769-85.

PMID:
12891063
13.

Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast.

Ekouevi DK, Touré R, Becquet R, Viho I, Sakarovitch C, Rouet F, Towne-Gold B, Fassinou P, Leroy V, Blanche S, Dabis F; Agence Nationale de Recherches Sur le SIDA 1201/1202 Ditrame Plus Study Group..

Pediatrics. 2006 Oct;118(4):e1071-7. Epub 2006 Sep 1.

14.
15.

Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.

Benhammou V, Warszawski J, Bellec S, Doz F, André N, Lacour B, Levine M, Bavoux F, Tubiana R, Mandelbrot L, Clavel J, Blanche S; ANRS-Enquête Périnatale Française..

AIDS. 2008 Oct 18;22(16):2165-77. doi: 10.1097/QAD.0b013e328311d18b. Erratum in: AIDS. 2012 May 15;26(8):1047. Carbillon, François F [corrected to Carbillon, L].

PMID:
18832880
16.

Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.

Neubert J, Pfeffer M, Borkhardt A, Niehues T, Adams O, Bolten M, Reuter S, Stannigel H, Laws HJ.

BMC Pregnancy Childbirth. 2013 Jan 24;13:22. doi: 10.1186/1471-2393-13-22.

17.

Altered heterochromatin organization after perinatal exposure to zidovudine.

Senda S, Blanche S, Costagliola D, Cibert C, Nigon F, Firtion G, Floch C, Parat S, Viegas-Péquignot E.

Antivir Ther. 2007;12(2):179-87. Erratum in: Antivir Ther. 2007;12(3):429.

PMID:
17503660
18.

Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Bhana N, Ormrod D, Perry CM, Figgitt DP.

Paediatr Drugs. 2002;4(8):515-53. Review.

PMID:
12126455
19.

Neurological disorders after zidovudine exposure in utero.

[No authors listed]

Prescrire Int. 1999 Dec;8(44):181-2.

PMID:
11503820
20.

Prevention of mother-child HIV transmission: progress and problems.

[No authors listed]

Prescrire Int. 2000 Jun;9(47):92-5.

PMID:
11010753

Supplemental Content

Support Center